Live Breaking News & Updates on Barbara Ann Karmanos

Stay updated with breaking news from Barbara ann karmanos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product


Article content
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in the Phase III ZIRCON
1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (
89Zr-girentuximab) in the United States.
The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth.
The ZIRCON trial, which includes twelve participating clinical study sites across the U.S. and Canada, initiated patient recruitment in U.S. on Friday, with the first patients being dosed with TLX250-CDx at University of California, Los Angeles (UCLA), and Seattle Cancer Care Alliance, University of Washingt ....

New York , United States , Emory University , Los Angeles , Sloan Kettering , Christian Behrenbruch , Barbara Ann Karmanos , Delphine Chen , Davidn Cade , Colin Hayward , Allan Pantuck , John Hopkins , Mortimerb Davis , Telix Pharmaceuticals , Centre De Recherche , Drug Administration , Centre Hospitalier , Australian Securities Exchange , Washington University , University Of Washington , Seattle Cancer Care Alliance , European Union , Telix Pharmaceuticals Limited , Cdx At University Of California , Therapeutic Goods Administration , Chief Medical Officer ,